The development of gene targeting strategies for specific modification of genomic DNA in human somatic cells has provided a potential gene therapy for the treatment of inherited diseases. One approach, small fragment homologous replacement (SFHR), directly targets and modifies specific genomic sequences with small fragments of exogenous DNA (400-800 bp) that are homologous to genomic sequences except for the desired modification. This approach has been effective for the in vitro modification of exon 10 in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human airway epithelial cells. As another step in the development of SFHR for gene therapy, studies were carried out to target and modify specific genKeywords: gene targeting; gene therapy; cystic fibrosis; DNA delivery vehicles Currently, there are two primary gene therapy approaches for the treatment of inherited disorders. One approach involves the introduction of a cDNA version of a normal gene via viral or plasmid vector into cells, or 'gene complementation'. 1 The other strategy involves site-specific modification of mutant DNA sequences by 'gene targeting'. 2, 3 Gene targeting has several advantages over gene complementation, including long-term and tissue-specific expression of the functional gene, no introduction of foreign sequences and no immune response. Several gene-targeting approaches have been developed for correction of mutations associated with genetic disease. These include RNA/DNA chimeric oligos, [4] [5] [6] [7] [8] triplex forming oligonucleotides, 9, 10 and small fragment homologous replacement (SFHR).
omic sequences in exon 10 of the mouse CFTR (mCFTR) in vivo. Small DNA fragments (783 bp), homologous to mCFTR except for a 3-bp deletion (⌬F508) and a silent mutation which introduces a unique restriction site (KpnI), were instilled into the lungs of normal mice using four different DNA vehicles (AVE, LipofectAMINE, DDAB, SuperFect). Successful modification was determined by PCR amplification of DNA or mRNA-derived cDNA followed by KpnI digestion. The results of these studies showed that SFHR can be used as a gene therapy to introduce specific modifications into the cells of clinically affected organs and that the cells will express the new sequence. Gene Therapy (2001) 8, 961-965.
small DNA, fragments are essentially homologous to the targeted endogenous DNA sequences except for the particular base pairs (bp) that encode for the desired modification. To date, SFHR has been used to modify both extra-chromosomal or episomal, 14, 15 and genomic DNA sequences in human transformed and primary cells in vitro. 12, 13 Site-specific deletion of episomal DNA sequences has been shown by the targeted correction of a defective selectable marker gene, the Zeocin resistance gene, following transient co-transfection of a plasmid containing the defective gene and small DNA fragments into transformed human epithelial cells from cystic fibrosis (CF) patients. 14, 15 Site-specific addition of genomic DNA sequences has been demonstrated by the correction of a 3-bp deletion in the CFTR (CF transmembrane conductance regulator) gene of transformed and primary CF (⌬F508 genotype) airway epithelial cells that resulted in a normal, Cl − ion transport phenotype. 12, 13 In these experiments, a specific base pair modification (silent mutation) was concomitantly introduced by SFHR to create a novel restriction enzyme cleavage site within CFTR as a tag.
The efficacy of SFHR as a gene therapy has yet to be tested in vivo. One difficulty in going from in vitro to in Gene Therapy vivo experiments is that the conditions relevant to transfer (the delivery vehicle, the target, and the route of delivery) are different. For the experiments presented here, the transfer conditions were established as follows. Given the already overwhelming body of literature on different compounds for the delivery of DNA in vivo, 16, 17 the delivery vehicles that were chosen have either been previously used in vitro or have been tested for in vivo delivery into the airways with reporter genes. The decision for target choice was based on the fact that the primary cause of death and morbidity in CF is due to lung infections; therefore, the development of an SFHR-based gene therapy for CF would include delivery into the lung. 18 Studies were performed in the lungs of normal mice as a proof of principle. Finally, the route of delivery was intratracheal instillation thereby ensuring direct delivery of replacement fragment into the target organ, ie the airways of the lung, 19, 20 as opposed to aerosol 21 or systemic delivery. 22 The potential of SFHR as an in vivo gene therapy was assayed using small DNA fragments (783 bp) that were designed to introduce a site-specific 3-bp deletion in exon 10 of the endogenous mouse CFTR (mCFTR) sequence in lung cells of normal mice thereby creating a ⌬F508 genotype. As an additional tag, the small DNA fragments contained a silent mutation that introduced a unique KpnI restriction enzyme cleavage site into the targeted regions in the mCFTR (Figure 1 ). The fragments were complexed with one of four artificial DNA delivery vehicles: condensing agent and phospholipid (artificial viral envelope -AVE), 17 cationic lipid (LipofectAMINE; Life Technologies) or dimethyl-dioctadecyl-ammoniumbromide (DDAB), 23 or cationic polyamidoamine (starburst dendrimer, SuperFect, Qiagen) 24 and introduced into the lungs of normal mice via intratracheal instillation. Successful site-specific deletion of 3-bp in the mCFTR gene was determined by PCR amplification of DNA or mRNA-derived cDNA followed by KpnI restriction digest. Allele-specific primers, mCF3-N and mCF3-⌬F, were used to distinguish between normal and ⌬F508 sequences ( Figure 1 and Table 1) .
Site-specific modification of exon 10 in normal mCFTR by SFHR resulted in the expression of ⌬F508 RNA as indicated by allele-specific RT-PCR analysis of RNA from the lungs of mice 3 days after intratracheal instillation of 4 g of fragment via delivery vehicles AVE (Figure 2 ), LipofectAMINE ( Figure 3 ) or DDAB (Figure 4a ). In addition, PCR amplicons could be cut by KpnI thus indicating that in addition to the deletion of 3 bp, the single base pair that gives rise to this unique restriction site, was modified ( Figure 2 and Figure 4b ). Overall, six of 13 (46%) mice tested at this dose (4 g) were positive for the modification. Successful modification was most reproducible at this dose with the DNA vehicle AVE (three of three mice, or 100%) followed by LipofectAM-INE (two of three mice, or 66%) then by DDAB (one of two mice, or 50%). Modification was least reproducible with SuperFect (none of five mice, or 0%). The success of modification remained the same with DDAB when the amount of fragment was increased to 20 g (one of two mice, Figure 4 ) and with LipofectAMINE when the amount of time after instillation was increased to 7 days (two of three mice, Figure 5 ). These studies demonstrate SFHR-mediated site-specific deletion of 3 bp in endogenous mCFTR DNA and RNA in the lung cells of normal mice. These results cannot be readily attributed to a PCR artifact that entails the fragment serving as a primer in PCR amplifications. In previous experiments, false positives were not observed after allele-specific PCR amplification of genomic DNA mixed with up to the equivalent of 1 000 000 small DNA fragments per cell. 12 In the experiments presented here, mouse lungs were exposed to a maximum of ෂ57 000 fragments per cell given an average lung weight of 160 mg. The actual number of fragments that were successfully delivered into cells and therefore present at the time Gene Therapy
Figure 3 In this study, 4 g of fragment was instilled into the lungs of three mice after being complexed with 7.2 l of LipofectAMINE (1:2 negative to positive charge ratio). Tissue was harvested 3 days after transfection. Allele-specific PCR amplification (mCF11/mCF3-⌬F) was performed on mRNA-derived cDNA from lung tissue from all three mice (1-3) as well as a control (N -normal) mouse that received saline solution and a ⌬F508 homozygous mouse (⌬F). The results confirm expression of exogenous ⌬F508 sequences in two of the transfected mice (2 and 3) but not in mouse 1 or the control. There was no spurious amplification from samples that were not reverse-transcribed. The differences in PCR band intensity are attributed to amplification conditions and are not necessarily reflective of the amount of CFTR-RNA present in the samples.
of DNA and RNA isolation is less than 40%, resulting in at most 22 800 small DNA fragments per cell. 25 In addition, a false positive due to contaminating DNA (genomic or small fragment) in the RT-PCR amplification reactions is highly unlikely because each RNA sample was treated with DNase (see Figure 1 legend) .
Expression of ⌬F508 mCFTR mRNA was observed in lung tissue after intratracheal instillation of the small DNA fragment with three of four DNA delivery vehicles tested using DNA:vehicle ratios that were established in vitro. While it is clear that there are multiple factors that can influence the success of modification by SFHR other than the delivery vehicle, the data suggests that AVE Ͼ LipofectAMINE Ͼ DDAB Ͼ SuperFect in terms of reproducibility. The finding that there was no modification after intratracheal instillation with the cationic polyamidoamine (SuperFect) may be due to the delivery system. However, we cannot rule out the possibility that those individual variations in the mice and/or the transfection conditions may play a role in the effectiveness of an individual delivery vehicle. While the results of these experiments demonstrate SFHR-mediated modification, the actual frequency of modification was not determined. The PCR amplification conditions used for analysis were designed to detect allele-specific modification of DNA and RNA sequences. To assess frequency, the PCR amplification will need to be normalized to an external control. In addition, the different rates of RNA expression and degradation between normal and ⌬F508 mice need to be considered for such subsequent evaluation.
The findings presented here support observations by others that in vitro conditions can be extrapolated to in vivo transfection, especially when the in vitro studies were carried out in a relevant cell type. 16, 26 Given the observation that at least one mouse per experiment showed successful modification with lipid vehicles, in vitro experiments can be useful for defining some of the conditions for effective in vivo DNA transfer with lipids. The ultimate optimization of transfection efficiency will; however, require analysis in vivo.
On the other hand, in vitro conditions are not always an indication of in vivo success for some vehicles. In in vitro studies, the polyamidomine dendrimer was superior to the other delivery systems described here in airway epithelial cells. 27 However, other studies have found that the conditions for dendrimer-mediated intratracheal delivery of the DNA need to be carefully titrated. 28 As such, it is highly probable that in our case, the conditions necessary for successful in vivo delivery were not the same as successful in vitro conditions. Systemic delivery of DNA by the dendrimer complex would be an alternative route that will need to be investigated further for optimal and specific delivery. 29 Finally, it is not obvious why successful modification was more reproducible with AVE than the other vehicles, although AVE is overall negatively charged, in contrast to the net positive surface charge of the other vehicles. One possibility is that AVE may be more effective in targeting the fragments to cells that express CFTR. Alternatively, LipofectAMINE, DDAB and SuperFect complexes may not readily dissociate in the cytoplasm to facilitate nuclear delivery. 14, 15 These results indicate that SFHR has potential as a gene therapy. Previous studies have shown that cDNA can be delivered to the lung with cationic lipids for gene complementation. 20, 30, 31 The results presented here show that DNA fragments can also be delivered to the lung and that SFHR-mediated gene targeting is a viable route for lung/airway SFHR-mediated gene targeting. The fragments, at the doses tested here, are delivered to the appropriate cells, ie those cells expressing mCFTR mRNA. Moreover, given that ⌬F508 mCFTR DNA was detected 7 days after transfection, the results suggest that SFHR effects a permanent genomic modification that would lead to RNA expression throughout the lifetime of the cell. Finally, the findings indicate that SFHR is precise in that ⌬F508 mCFTR mRNA sequences were only detected within the target organs, the lung and lower air-ways, but not in the trachea, liver, or heart ( Figure 2) . Thus, SFHR appears to have therapeutic potential within the airway epithelium, and with further study could be developed into a viable gene therapy for CF airways.
